Back مجموعة الصين الوطنية للصناعات الدوائية Arabic China National Pharmaceutical Group Catalan Sinopharm (firmao) Esperanto Sinopharm (compañía) Spanish گروه دارویی ملی چین Persian סינופארם HE China National Pharmaceutical Group ID China National Pharmaceutical Group Italian シノファーム Japanese ჩინეთის ეროვნული ფარმაცევტული ჯგუფი Georgian
39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E
&sq=Google&lang=en&file=File:China_National_Pharmaceutical_Group_Corporation.png) | |||||||
&sq=Google&lang=en&file=File:Sinopharm_Building_(20230206145912).jpg) Headquarters | |||||||
| Sinopharm | |||||||
| Company type | State-owned enterprise | ||||||
| Industry | |||||||
| Founded | November 26, 1998 | ||||||
| Headquarters | 20 Zhichun Road, Haidian District, Beijing , China | ||||||
Area served | China, exported worldwide | ||||||
Key people | Liu Jingzhen (chairman & Chinese Communist Party Committee Secretary)[1][2] | ||||||
| Products | |||||||
| Revenue |  CN¥247.110 billion (2014) | ||||||
| CN¥8.758 billion (2014) | |||||||
| CN¥2.705 billion (2014) | |||||||
| Total assets | CN¥199.192 billion (2014) | ||||||
| Total equity | CN¥31.944 billion (2014) | ||||||
| Owner | Chinese central government (100%) | ||||||
| Parent | SASAC of the State Council | ||||||
| Subsidiaries |
| ||||||
| Chinese name | |||||||
| Simplified Chinese | 中国医药集团总公司 | ||||||
| Traditional Chinese | 中國醫藥集團總公司 | ||||||
| |||||||
| short Chinese name | |||||||
| Simplified Chinese | 国药集团 | ||||||
| Traditional Chinese | 國藥集團 | ||||||
| |||||||
| Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3] | |||||||
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[6]
- ^ "中国医药集团有限公司主要领导调整" (in Chinese). Sinopharm. Archived from the original on 2022-09-08. Retrieved 2021-08-24.
- ^ "Liu Jingzhen". Bloomberg.
- ^ "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
- ^ "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
- ^ "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
- ^ "Global 500".